Pharmaceuticals

Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2019 /PRNewswire/ -- Adagene, Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences.  During the Festival of Biologics confere...

2019-10-26 18:01 748

World first clinical trial commenced in alcohol use disorder

MELBOURNE, Australia, Oct. 24, 2019 /PRNewswire/ -- A medication currently used to treat insomnia may also be effective in preventing alcohol intake and relapse in alcohol use disorder, according to researchers at the Florey Institute of Neuroscience and Mental Health. A world-first clinical stu...

2019-10-24 12:01 353

GN Corporation and Edogawa Evolutionary Laboratory of Science Cosponsor International Academic Conference, NCRM NICHE 2019, on October 15, 2019

KOFU, Japan and TOKYO, Oct. 21, 2019 /PRNewswire/ -- GN Corporation Co., Ltd., a Japanese firm involved in research and development of technology in regenerative medicine, and Edogawa Evolutionary Laboratory of Science(EELS), a unit ofTokyo's Edogawa Hospital, cosponsored NCRM NICHE 2019 (www.ncr...

2019-10-21 14:00 414

Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...

2019-10-18 20:30 9686

China Biologic Special Committee Retains Financial Advisor and Legal Counsel

BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...

2019-10-17 20:00 10093

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage drug discovery and development company which devotes its efforts towards discovering, developing and delivering innovative medicines that help patients prevail over liver diseases, announced today that it has dos...

2019-10-16 18:00 283

Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis

MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 15, 2019 /PRNewswire/ -- Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases, announced today that it enrolled t...

2019-10-15 05:58 355

STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal

SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients inAustralia, New Zealand and throughout SE Asia. Under the ...

2019-10-14 14:00 354

Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...

2019-10-11 13:00 508

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...

2019-10-04 13:40 644

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 498

Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...

2019-10-02 12:01 7647

Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval

SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...

2019-10-01 04:00 7116

Yuyu Pharma Unveils New Corporate Logo

SEOUL, South Korea, Sept. 30, 2019 /PRNewswire/ -- Yuyu's corporate logo was first created in 1941 to honor the company's proud history and highlight Yuyu's image as a company on the cutting-edge of the industry.  Yuyu Pharma ...

2019-09-30 21:00 405

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...

2019-09-30 16:30 338

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...

2019-09-30 13:41 281

The 10th China (Taizhou) International Medical Expo successfully ended

NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th China (Taizhou) International Medical Expo was held in China Medical City (CMS), according toChina (Taizhou) Medical Expo News Center.

2019-09-30 13:27 300

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...

2019-09-30 06:00 458

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...

2019-09-30 05:00 383

China Biologic Forms Special Committee to Review "Going Private" Proposal

BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...

2019-09-24 20:00 11364
1234567 ... 42